Then that is what they will have @Sector. This does not mean they need to increase production based on a trial that is not complete.
The vaccines were given money for production. MSB had to raise their own.
Like I said, if the trial is successful, then current supplies will be used. There is no need to increase production until trial results are out, or an approval is imminent.
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-433
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.353B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |